Charalambos Antoniades explains why coronary inflammation needs to be diagnosed and treated and shows how perivascular fat analysis from routine CTCA can provide a quantitative assessment of coronary inflammation.

Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

EASD 2021 Using data of four semaglutide trials, this exploratory analysis showed that both subcutaneous and oral semaglutide reduced high-sensitivity CRP in patients with T2DM.

What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

Levels of IL-6 in community-dwelling participants were associated with the development of HFpEF, independent of iron deficiency, anemia, and FGF23 upregulation.

This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.

ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.

A meta-analysis of 5 trials showed that colchicine reduced MACE by 25% compared to placebo or no colchicine with a low between-trial heterogeneity in a wide range of patients with coronary disease.

From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?

A subanalysis of COLCOT showed that initiation of colchicine within the first 3 days after MI significantly reduced the risk of an ischemic CV event compared to patients on placebo.

This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.